Oxford BioMedica PLC (OTCPK:OXBDF)
$ 5.35 0 (0%) Market Cap: 564.24 Mil Enterprise Value: 606.71 Mil PE Ratio: 0 PB Ratio: 6.78 GF Score: 69/100

Half Year 2020 Oxford BioMedica PLC Earnings Call Transcript

Sep 17, 2020 / 12:00PM GMT
Release Date Price: $11.24 (+2.18%)
Catherine Isted
Oxford Biomedica plc - Head of Corporate Development & IR

Good afternoon, ladies and gentlemen, and welcome to Oxford Biomedica's Interim Results Conference Call. We are delighted today to talk through what hopefully you agree is a strong set of results for the 6 months ended the 30th of June, on a backdrop of what for all of us has been unprecedented times.

As you'll see, Oxford Biomedica has never been busier, not only in our core area of lenti-based cell and gene therapy, but also in the fight against COVID through our work on AstraZeneca's vaccine. On the call with me today is our CEO, John Dawson; and CFO, Stuart Paynter. (Operator Instructions) And the presentation is being recorded. (Operator Instructions)

With that, I'd like to hand over to John Dawson.

John Dawson
Oxford Biomedica plc - CEO & Executive Director

Thank you, Catherine, and we're showing you currently the forward-looking statement slide. And during the presentation, we'll make forward-looking statements which cannot be relied upon.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot